iShares Biotechnology ETF
856 hedge funds and large institutions have $8.9B invested in iShares Biotechnology ETF in 2020 Q4 according to their latest regulatory filings, with 143 funds opening new positions, 265 increasing their positions, 269 reducing their positions, and 58 closing their positions.
147% more first-time investments, than exits
New positions opened: 143 | Existing positions closed: 58
21% more capital invested
Capital invested by funds: $7.36B → $8.9B (+$1.54B)
9% more funds holding
Funds holding: 784 → 856 (+72)
4.48% more ownership
Funds ownership: 80.86% → 85.34% (+4.5%)
1% less repeat investments, than reductions
Existing positions increased: 265 | Existing positions reduced: 269
12% less funds holding in top 10
Funds holding in top 10: 17 → 15 (-2)
46% less call options, than puts
Call options by funds: $818M | Put options by funds: $1.5B
Top Buyers
| 1 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$643M |
| 2 |
Goldman Sachs
New York
|
+$376M |
| 3 |
Morgan Stanley
New York
|
+$157M |
| 4 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
+$143M |
| 5 |
Citigroup
New York
|
+$57.1M |
Top Sellers
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
-$391M |
| 2 |
JP Morgan Chase
New York
|
-$225M |
| 3 |
Barclays
London,
United Kingdom
|
-$100M |
| 4 |
N
Natixis
Paris,
France
|
-$67.7M |
| 5 |
Squarepoint
New York
|
-$29.3M |
IBB Hedge Fund Activity: Q4 2020 in Review
856 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q4 2020, worth a combined $8.9B — up 21% from $7.36B a quarter earlier.
Buyers outnumbered sellers: 143 funds opened new IBB positions and 58 closed out — a net gain of 85 holders — while 265 added to existing stakes and 269 trimmed.
The largest buyer was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, adding an estimated $643M. The largest seller was BNP Paribas Financial Markets, cutting an estimated $391M.
- 856 institutional investors held iShares Biotechnology ETF (IBB) as of Q4 2020, up from 784 in Q3 2020.
- Funds reported $8.9B of iShares Biotechnology ETF stock for Q4 2020, up 21% quarter-over-quarter.
- 143 funds opened new iShares Biotechnology ETF positions in Q4 2020 and 58 closed out, a net change of +85 holders.
- The largest iShares Biotechnology ETF buyer in Q4 2020 was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, an estimated $643M added.
- The largest iShares Biotechnology ETF seller in Q4 2020 was BNP Paribas Financial Markets, an estimated $391M sold.
Based on aggregated 13F filings for Q4 2020.